Therapeutic bronchoscopic interventions for nonmalignant central airway obstruction provide rapid and sustained improvement in symptoms and functional status

Shrestha, Prajowl; Madan, Karan; Hadda, Vijay; Upadhyay, Ashish; Mittal, Saurabh; Tiwari, Pawan; Pandey, R M; Garg, Rakesh; Khilnani, Gopi C; Guleria, Randeep

doi:10.4103/lungindia.lungindia_476_19

Cited by 4 publications

(2 citation statements)

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ECOG PS score was not only an indicator to determine whether cancer patients should receive chemotherapy but also a prognostic factor for cancer patients [ 18 ]. Similar to the study reported by Ong, this study showed that patients with a high ECOG PS score [ 3 , 4 ] had a worse prognosis than patients with a low ECOG PS score [0–2] (the mean survival time was 3.85 months and 12.35 months, resp., P =0.004), indicating that patients with good PS might survive from stent implantation to prolong survival and improve oxygenation [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Study of Airway Stent Implantation in the Treatment of Patients with Malignant Central Airway Obstruction

Xing

Zeng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Airway stenting is a therapeutic option for malignant central airway obstructions (MCAO), including both intraluminal and extraluminal obstructions. The objective of this study is to investigate the clinical features and results of long-term improved prognosis for MCAO patients after airway stent implantation. Methods. Ninety-eight MCAO patients who underwent stent placement in our hospital from January 2013 to April 2020 were included in this study. The data included baseline data, clinical characteristics, laboratory test data, stent implantation data, and treatment as well as survival after stent implantation. The survival rates among individuals were compared via log-rank tests. Potential prognostic factors were identified using multivariate cox hazard regression models. Results. A retrospective analysis of these patients was generated. MCAO was mainly caused by lung cancer (53/98, 54.08%), esophageal cancer (22/98, 22.45%), and thyroid cancer (3/98, 3.06%). The median survival time of participants was 5.5 months. Univariate analysis indicated that the survival rate was related to primary disease, ECOG PS score, stent site, hemoglobin (Hb), albumin (ALB), and serum lactate dehydrogenase (LDH) ( P < 0.05 ). The cox risk regression model showed that the survival rate was significantly influenced by ECOG PS score (OR = 3.468, 95%CI = 1.426–8.432, P = 0.006 ) and stent site (OR = 1.544, 95%CI = 1.057–2.255, P = 0.025 ). Conclusions. Compared with the site of stent placement, the ECOG PS score is the primary factor in the survival rate of MCAO patients after airway stenting.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Study of Airway Stent Implantation in the Treatment of Patients with Malignant Central Airway Obstruction

Xing

Zeng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Patients facing malignant central airway obstruction not only contend with an unfavorable overall prognosis but also endure severe respiratory symptoms and a diminished quality of life ( 8 – 10 ). The management of the case under discussion was particularly arduous due to the disease’s advanced stage and the patient’s deteriorating clinical state, marked by recurrent pulmonary infections and severe respiratory distress stemming from central airway obstruction ( 11 , 12 ). While bronchoscopy and stent placement represent the primary approaches for addressing atelectasis, they do not constitute a cure for the underlying tumor ( 13 – 15 ).…”

Section: Introductionmentioning

confidence: 99%

Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis

Liu,

Zhang,

Zhang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aims to explore the clinical application of bronchial artery chemoembolization (BACE) in managing refractory central lung cancer with atelectasis.MethodsThe retrospective case series includes patients diagnosed with refractory central lung cancer and atelectasis who underwent BACE treatment at Yueyang Integrated Traditional Chinese and Western Medicine Hospital, affiliated with Shanghai University of Traditional Chinese Medicine, from January 2012 to December 2021.ResultsAll 30 patients with lung cancer successfully underwent BACE procedures. Their ages ranged from 62 to 88 years, with an average age of 67.53. The treatment interval was 21 days, and the treatment cycle ranged from 2 to 12 times, averaging 4.13 times. During the BACE procedures, the Karnofsky Performance Status (KPS) score after 2 to 3 BACE cycles showed a significant improvement (82.0 ± 10.1 vs 68.3 ± 14.0, P < 0.001) than that of before BACE. Only nutritional support and symptomatic treatment were performed after BACE, and no major hemoptysis were observed. During follow-up, 23 cases resulted in mortality, while seven survived. The median progression-free survival (PFS) and overall survival (OS) were 7.0 (95% CI: 4.6–9.4) and 10.0 (95% CI: 6.2–13.8) months, respectively, with 1-, 2-, and 3-year survival rates of 84.0%, 53.5%, and 11.3%, respectively. Eight cases exhibited bronchial recanalization and relief of atelectasis. According to the RECIST scale, there were 4 cases of complete response (CR), 16 cases of partial response (PR), 9 cases of stable disease (SD), and 1 case of progressive disease (PD). No serious adverse events were reported.ConclusionBACE might be a safe intervention for refractory central lung cancer accompanied by atelectasis. The procedure exhibits satisfactory outcomes in tumor control, atelectasis relief, and enhancement of quality of life, warranting further investigation.

show abstract

The bleeding risk and safety of multiple treatments by bronchoscopy in patients with central airway stenosis

Jin

et al. 2023

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Therapeutic bronchoscopic interventions for nonmalignant central airway obstruction provide rapid and sustained improvement in symptoms and functional status

Cited by 4 publications

References 20 publications

Clinical Study of Airway Stent Implantation in the Treatment of Patients with Malignant Central Airway Obstruction

Clinical Study of Airway Stent Implantation in the Treatment of Patients with Malignant Central Airway Obstruction

Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis

The bleeding risk and safety of multiple treatments by bronchoscopy in patients with central airway stenosis

Contact Info

Product

Resources

About